Cinctive Capital Management LP Cuts Stake in Sanofi (NASDAQ:SNY)

Cinctive Capital Management LP lessened its stake in Sanofi (NASDAQ:SNY) by 30.2% during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 108,317 shares of the company’s stock after selling 46,792 shares during the quarter. Cinctive Capital Management LP’s holdings in Sanofi were worth $5,224,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the stock. Raymond James Financial Inc. purchased a new position in Sanofi during the 4th quarter valued at approximately $135,933,000. Boston Partners boosted its position in shares of Sanofi by 86.4% during the 4th quarter. Boston Partners now owns 5,396,531 shares of the company’s stock valued at $260,607,000 after acquiring an additional 2,501,073 shares during the last quarter. Magnetar Financial LLC grew its holdings in shares of Sanofi by 104.3% in the fourth quarter. Magnetar Financial LLC now owns 3,340,317 shares of the company’s stock valued at $161,103,000 after purchasing an additional 1,705,148 shares in the last quarter. DAVENPORT & Co LLC increased its position in Sanofi by 40.7% in the fourth quarter. DAVENPORT & Co LLC now owns 2,295,569 shares of the company’s stock worth $110,715,000 after purchasing an additional 664,455 shares during the last quarter. Finally, Thrivent Financial for Lutherans raised its stake in Sanofi by 36.0% during the fourth quarter. Thrivent Financial for Lutherans now owns 1,943,761 shares of the company’s stock valued at $93,774,000 after purchasing an additional 514,542 shares in the last quarter. Institutional investors own 14.04% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on SNY. Sanford C. Bernstein upgraded shares of Sanofi to a “strong-buy” rating in a report on Thursday, January 30th. The Goldman Sachs Group started coverage on Sanofi in a research report on Friday, March 21st. They set a “neutral” rating and a $65.00 price objective on the stock. StockNews.com lowered Sanofi from a “buy” rating to a “hold” rating in a research note on Thursday, December 12th. Finally, Deutsche Bank Aktiengesellschaft raised Sanofi from a “sell” rating to a “hold” rating in a research report on Thursday, January 30th. Three equities research analysts have rated the stock with a hold rating, one has given a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $62.50.

Sanofi Stock Performance

Sanofi stock opened at $53.95 on Thursday. The company has a debt-to-equity ratio of 0.15, a current ratio of 1.46 and a quick ratio of 1.14. The firm has a market capitalization of $136.92 billion, a P/E ratio of 21.67, a price-to-earnings-growth ratio of 1.01 and a beta of 0.58. Sanofi has a 1-year low of $45.22 and a 1-year high of $60.12. The company’s 50-day moving average is $55.33 and its 200 day moving average is $52.74.

Sanofi (NASDAQ:SNY) last issued its quarterly earnings results on Thursday, January 30th. The company reported $0.70 earnings per share for the quarter, hitting the consensus estimate of $0.70. Sanofi had a return on equity of 25.61% and a net margin of 12.77%. Research analysts forecast that Sanofi will post 4.36 EPS for the current year.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.